Aurinia settles Teva patent suit, bars generic voclosporin launch until Dec. 7, 2036
PUBT · 1d ago
Share
Listen to the news
- Aurinia Pharmaceuticals settled patent litigation with Teva over a proposed U.S. generic voclosporin 7.9 mg capsule.
- Teva stipulated two Aurinia patents expiring in December 2037 are valid, enforceable, and would be infringed by U.S. sales.
- Settlement bars a Teva generic launch before Dec. 7, 2036, subject to defined contingencies.
- Any launch also depends on FDA approval for Teva’s abbreviated new drug application.
- Separate patent cases continue in New Jersey federal court against other generic challengers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260819509870) on August 19, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending